- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Pharmacy Cost Trends Expected to Continue in the Double Digits
Pharmacy cost trends are expected to increase 10% up from 6.3% the year before, with specialty pharmacy trends experiencing the largest increases, according to a survey from Aon Health.
Pharmacy cost trends are expected to increase 10% up from 6.3% the year before, with specialty pharmacy trends experiencing the largest increases, according to a survey from Aon Health. The estimated specialty pharmacy drugs cost trends only are 22.7% in 2015, up from an 18.2% increase in 2014.
Upcoming specialty drugs are contributing to the dramatic spike in the cost trends, according to John Malley, leader of Aon Health’s Innovation Pharmacy Team. Specifically, he noted oncology drugs will be the largest category of specialty drug approvals in the near future and cholesterol drugs may also have a significant impact.
“Carriers continue to see price inflation as the single largest driver of increased medical costs, but an aging population, unhealthy lifestyle choices and provider consolidation are also contributing to the trend increase," Tim Nimmer, global chief actuary for Aon Health, said in a statement.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Obesity at Cancer Diagnosis Linked to Worse Survival Outcomes in Pediatric Patients
January 13th 2025Pediatric patients considered obese at cancer diagnosis are linked to significantly worse survival outcomes, especially those with acute lymphoblastic leukemia and central nervous system tumors.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
FDA Approves Tislelizumab-jsgr as First-Line Therapy for HER2– Gastric Cancers
January 2nd 2025Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic HER2-negative (HER–) gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1.
Read More
